Let’s Talk About Ozempic (Updated Version)
GLP-1 agonists like semaglutide and tirzepatide represent the first reliable medical treatment for obesity, a condition affecting over 1 billion people and causing nearly 4 million deaths annually. More than 1 in 8 US adults have tried these drugs, contributing to the first historical decline in the country's obesity rate, while the WHO added them to its essential medicines list in late 2025. Unlike behavioral diets that typically fail as the body fights to regain weight, these medications extend the natural GLP-1 signal for up to a week to suppress appetite and regulate insulin resistance. This shift addresses the biological reality that obesity is driven by dysregulated hunger signals rather than a lack of self-control.
La santé des femmes, de l'ignorance à la reconnaissance | Documentaire | ARTE
Cardiovascular disease remains the leading cause of premature death for one in three women in France and Germany, yet medical standards historically rely on male physiological models, leading to fatal misdiagnoses. Case studies reveal that women often present atypical symptoms like shoulder pain and nausea rather than chest pain, causing emergency services to dismiss their conditions as anxiety or stress. Research by cardiologist Vera Regitz-Sagrzeck analyzing 17,000 coronary bypass procedures confirms that mortality rates for young women are significantly higher than for men of the same age due to these diagnostic biases. Consequently, the medical community's failure to account for biological differences in metabolism and tissue composition results in a critical loss of opportunity for timely intervention and survival.